MAZE
Maze Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$29.70
+7.88%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$28.13
From 52W high−42.71%
Volume1.30M
Market cap$1.65B
P/E (TTM)—
P/S (TTM)82.5x
Div yield—
Key dataOct 19, 2026
Open
$28.13
From 52W high
−42.71%
Volume
1.30M
Market cap
$1.65B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.0x
P/E (TTM)
—
RSI (14)
65.1
MomentumView details →
1D Return
+7.88%
YTD Return
−28.13%
SummaryUpdated Jun 1, 2026
Maze Therapeutics, Inc. (NASDAQ:MAZE) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in South San Francisco, California. Originally incorporated as Modulus Therapeutics, Inc., the company changed its name to Maze Therapeutics in September 2018. The company went public on January 31, 2025, representing one of the first biotechnology IPOs of the year. Maze focuses on developing precision medicines for serious diseases affecting the kidneys, cardiovascular system, and related metabolic conditions, with a particular emphasis on genetic-based therapeutic approaches.
Similar companies
Latest newsMore news →
Maze Therapeutics exchanged 2,776,007 shares of common stock for pre-funded warrants to purchase the same number of shares at an exercise price of $0.001 per share, under an agreement with four Frazier Life Sciences funds.3d agoMaze Therapeutics, Inc. announced that it will present data on its MZE829 and MZE782 programs at ASN Kidney Week 2026 in Denver, October 21–25.13d ago